Search results for "STEATOSIS"

showing 10 items of 248 documents

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.

2016

The PNPLA3 p.I148M, TM6SF2 p.E167K, and MBOAT7 rs641738 variants represent genetic risk factors for nonalcoholic fatty liver disease (NAFLD). Here we investigate if these polymorphisms modulate both steatosis and fibrosis in patients with NAFLD. We recruited 515 patients with NAFLD (age 16–88 years, 280 female patients). Liver biopsies were performed in 320 patients. PCR-based assays were used to genotype the PNPLA3, TM6SF2, and MBOAT7 variants. Carriers of the PNPLA3 and TM6SF2 risk alleles showed increased serum aspartate aminotransferase and alanine transaminase activities (P 0.05). The MBOAT7 variant was solely associated with increased fibrosis (P = 0.046). In the multivariate model, v…

0301 basic medicineMalePathologyBiopsyBiochemistryGastroenterologySeverity of Illness Index0302 clinical medicineEndocrinologyFibrosisNon-alcoholic Fatty Liver DiseaseGenotypeNonalcoholic fatty liver diseaseAged 80 and overeducation.field_of_studybiologyFatty liverMiddle AgedLiver030211 gastroenterology & hepatologyFemaleAdultmedicine.medical_specialtyAdolescentGenotypePolymorphism Single Nucleotide03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAdiponutrinGenetic Predisposition to DiseaseeducationAllelesGenetic Association StudiesAgedbusiness.industryMembrane ProteinsCell BiologyLipasemedicine.diseaseFibrosisFatty Liver030104 developmental biologyAlanine transaminasebiology.proteinSteatosisbusinessPatient-Oriented and Epidemiological ResearchAcyltransferasesTM6SF2Journal of lipid research
researchProduct

Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms.

2020

Diabetic dyslipidemia, characterized by increased plasma triglycerides and decreased HDL cholesterol levels, is a major factor contributing to nonalcoholic steatohepatitis and cardiovascular risk in type 2 diabetes. Activation of the cannabinoid-1 receptor (CB1R) and activation of inducible nitric oxide synthase (iNOS) are associated with nonalcoholic steatohepatitis progression. Here, we tested whether dual-targeting inhibition of hepatic CB1R and iNOS improves diabetic dyslipidemia in mice with diet-induced obesity (DIO mice). DIO mice were treated for 14 days with (S)-MRI-1867, a peripherally restricted hybrid inhibitor of CB1R and iNOS. (R)-MRI-1867, the CB1R-inactive stereoisomer that …

0301 basic medicineMaleVery low-density lipoproteinEndocrinology Diabetes and MetabolismNitric Oxide Synthase Type II[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB][SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyMice0302 clinical medicineReceptor Cannabinoid CB1[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Receptor[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Cells Cultured[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismbiology[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biomolecules [q-bio.BM]Nitric oxide synthaseLiver[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyKexinlipids (amino acids peptides and proteins)medicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]LipoproteinsImmunoblotting030209 endocrinology & metabolismReal-Time Polymerase Chain Reaction03 medical and health sciencesInternal medicineCommentariesInternal MedicinemedicineAnimalsObesity[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Dyslipidemiasbusiness.industry[SDV.OT] Life Sciences [q-bio]/Other [q-bio.OT]PCSK9nutritional and metabolic diseases[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologymedicine.diseaseLipid Metabolism[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMice Inbred C57BL030104 developmental biologyEndocrinologyGlucoseLDL receptorbiology.proteinHepatocytes[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologySteatosisbusinessDyslipidemia
researchProduct

Elevated Fatty Liver Index as a Risk Factor for All‐Cause Mortality in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients (ANRS CO13 …

2020

International audience; Background and aims: Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic complications and liver-related events, which are both associated with hepatic steatosis and its progressive form, nonalcoholic steatohepatitis, a known risk factor for mortality. The fatty liver index (FLI), a noninvasive steatosis biomarker, has recently drawn attention for its clinical prognostic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated. Using a Cox proportional hazards model for mortality from all causes, with data from the French National Agency for Research on A…

0301 basic medicineMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatment[SDV]Life Sciences [q-bio]HIV InfectionsLiver transplantationmedicine.disease_causeGastroenterologyAntiviral AgentsCohort Studies03 medical and health sciences0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicineCause of DeathmedicineHumansRisk factorComputingMilieux_MISCELLANEOUSHepatologybusiness.industryCoinfectionHazard ratioFatty liverHepatitis C ChronicMiddle Agedmedicine.disease3. Good healthFatty Liver[SDV] Life Sciences [q-bio]030104 developmental biology[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases030211 gastroenterology & hepatologyFemaleFranceSteatosisViral hepatitisbusiness
researchProduct

Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet

2016

Aim: The purpose of the present study was to investigate the influence of endogenous glucagon-like peptide-2 (GLP-2) on lipid profile in mice fed a standard diet (STD) or a high-fat diet (HFD). Materials and methods: HFD- and age-matched STD mice were injected once a day with GLP-2 (3-33), a GLP-2 receptor (GLP-2R) antagonist, or vehicle for 4 weeks. Results: HFD mice displayed increased intrahepatic lipid concentration and hepatic steatosis and higher plasma concentrations of cholesterol, LDL, AST, and ALT than STD mice. No difference was observed in lipid fecal elimination. In STD mice, the chronic treatment with GLP-2 (3-33) did not affect any parameter, while in HFD mice, it enhanced pl…

0301 basic medicineMalemedicine.medical_specialtyobesityEndogenyBiologyDiet High-FatliverSettore BIO/09 - Fisiologia03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineInsulin resistanceEndocrinologyMetabolic DiseaseslipidInternal medicineinsulin resistancemedicineGlucagon-Like Peptide 2AnimalsReceptormedicine.diagnostic_testCholesterolSettore BIO/16 - Anatomia Umanadigestive oral and skin physiologyAntagonistGeneral Medicinemedicine.diseaseGlucagon-like peptide-2LipidsPeptide FragmentsMice Inbred C57BL030104 developmental biologyEndocrinologychemistrylipids (amino acids peptides and proteins)030211 gastroenterology & hepatologySteatosisLipid profileGLP-2hormones hormone substitutes and hormone antagonists
researchProduct

A "systems medicine" approach to the study of non-alcoholic fatty liver disease

2016

a b s t r a c t The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diag- nosis criteria, and new endpoints of clinical trials).…

0301 basic medicinePathologymedicine.medical_specialtyFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Gastroenterology; HepatologySystems AnalysisSystems biologyPersonalizedPopulationDiseaseBioinformatics03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineFatty liverNAFLDFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicinemedicineHumansFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Hepatology; GastroenterologyeducationFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Disease Progression; Humans; Non-alcoholic Fatty Liver Disease; Phenotype; Risk Factors; Systems Biology; Systems Analysis; Medicine (all); Hepatology; Gastroenterologyeducation.field_of_studyHepatologybusiness.industrySystems BiologySettore MED/09 - MEDICINA INTERNAFatty liverGastroenterologyNASHHepatologymedicine.diseaseSystems medicineClinical trial030104 developmental biologyPhenotypeSystems medicineDisease ProgressionMedicine030211 gastroenterology & hepatologySteatosisbusiness
researchProduct

Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.

2017

Background and aims A recent meta-analysis revealed that the genotype PNPLA3 rs738409 GG is associated with a higher risk of hepatic steatosis (HS) in Caucasian patients with chronic hepatitis C (CHC). However, controversial results were found regarding Asian populations. Furthermore, previous studies have shown a negative association between interferon lambda 3 (IFNL3) rs12979860 CC and HS in Caucasian CHC patients, but there have been no reports indicating any such association in Asian populations. In this study, then, we investigated the association of PNPLA3 and IFNL3 polymorphisms with HS in Asian CHC patients. Methods We enrolled consecutive CHC patients who underwent liver biopsy pri…

0301 basic medicineRNA virusesMaleSteatosisHeredityPhysiologylcsh:MedicineHepacivirusChronic liver diseasePathology and Laboratory MedicineGastroenterologyBody Mass IndexCytopathologyLiver disease0302 clinical medicineEndocrinologyGenotypeMedicine and Health Scienceslcsh:ScienceMultidisciplinaryAlcohol Consumptionmedicine.diagnostic_testHepatitis C virusFatty liverHepatitis CMedical microbiologyMiddle AgedGenetic MappingPhysiological ParametersLiverLiver biopsyViruses030211 gastroenterology & hepatologyFemalePathogensResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersVariant GenotypesMicrobiologyPolymorphism Single Nucleotide03 medical and health sciencesAsian PeopleInternal medicinemedicineGeneticsDiabetes MellitusHumansGenetic Predisposition to DiseaseAllelesGenetic Association StudiesNutritionAgedFlavivirusesbusiness.industryInterleukinsBody Weightlcsh:ROrganismsViral pathogensBiology and Life SciencesMembrane ProteinsLipaseHepatitis C Chronicmedicine.diseaseFibrosisHepatitis virusesDietMicrobial pathogensFatty Liver030104 developmental biologyAnatomical PathologyGenetic LociMetabolic Disorderslcsh:QInterferonsSteatosisbusinessBody mass indexDevelopmental BiologyPLoS ONE
researchProduct

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6…

2019

The objective was to evaluate the effects of 6 months of supplementation with Altilix&reg

0301 basic medicineSettore MED/09 - Medicina Internacynaragenetic structuresPlacebo-controlled study030204 cardiovascular system & hematologySettore BIO/09 - FisiologiaGastroenterology0302 clinical medicineDiabetes mellitusimmune system diseasescardiovascular diseasehemic and lymphatic diseasesBrachial arteryLuteolinNutrition and Dieteticsdiabetes mellituFatty liverhemic and immune systemsDietary supplementsMetabolic syndromeCardiovascular diseasesLivertype 2diabetes mellitusChlorogenic Acidlcsh:Nutrition. Foods and food supplymedicine.medical_specialtyWaistlcsh:TX341-641chemical and pharmacologic phenomenaCynaraPlacebometabolic syndromedietary supplements03 medical and health sciencesDouble-Blind MethodInternal medicineDiabetes mellitusmedicine.arterymedicinebusiness.industrynon-alcoholic fatty liver diseasemedicine.diseasecardiovascular diseases030104 developmental biologydietary supplementSteatosisMetabolic syndromebusinessFood ScienceNon-alcoholic fatty liver disease
researchProduct

Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS

2017

Background and aims Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) recognize obesity and insulin resistance (IR) as common pathogenic background. We assessed 1) whether PCOS is a risk factor for steatosis, and 2) the impact, in PCOS patients, of IR and hyperandrogenism on steatosis and fibrosis. Methods We considered 202 consecutive Italian PCOS nondiabetic patients and 101 age-matched controls. PCOS was diagnosed applying the Rotterdam diagnostic criteria. Steatosis was diagnosed if hepatic steatosis index (HSI) >36, while fibrosis by using the FIB-4 score. As surrogate estimate of insulin sensitivity we considered the insulin sensitivity index (ISI). Free an…

0301 basic medicineSteatosisendocrine system diseasesPhysiologylcsh:MedicinePathology and Laboratory MedicineBiochemistryBody Mass IndexCytopathology0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseMedicine and Health SciencesInsulinlcsh:ScienceMultidisciplinaryLiver DiseasesFatty liverMiddle AgedPolycystic ovaryLipidsCholesterolOncologyPhysiological Parameters030211 gastroenterology & hepatologyFemalePolycystic Ovary SyndromeResearch ArticleAdultmedicine.medical_specialtyGastroenterology and Hepatology03 medical and health sciencesInsulin resistanceInternal medicinemedicineHumansObesityRisk factorTriglyceridesDiabetic Endocrinologybusiness.industryFree androgen indexHyperandrogenismCholesterol HDLBody Weightlcsh:RCancers and NeoplasmsBiology and Life Sciencesmedicine.diseaseFibrosisHormonesFatty Liver030104 developmental biologyEndocrinologyAnatomical Pathologylcsh:QSteatosisInsulin ResistancebusinessHyperandrogenismGynecological TumorsDevelopmental Biologyinsulin resistance PCOS
researchProduct

Human Upcyte Hepatocytes: Characterization of the Hepatic Phenotype and Evaluation for Acute and Long-Term Hepatotoxicity Routine Testing

2016

The capacity of human hepatic cell-based models to predict hepatotoxicity depends on the functional performance of cells. The major limitations of human hepatocytes include the scarce availability and rapid loss of the hepatic phenotype. Hepatoma cells are readily available and easy to handle, but are metabolically poor compared with hepatocytes. Recently developed human upcyte hepatocytes offer the advantage of combining many features of primary hepatocytes with the unlimited availability of hepatoma cells. We analyzed the phenotype of upcyte hepatocytes comparatively with HepG2 cells and adult primary human hepatocytes to characterize their functional features as a differentiated hepatic …

0301 basic medicineTime FactorsPrimary Cell CultureTransfectionToxicologyRisk AssessmentTranscriptome03 medical and health sciences0302 clinical medicineMetabolomicsCytochrome P-450 Enzyme SystemIn vivoToxicity TestsmedicineHumansChildGlycogen synthaseDose-Response Relationship DrugbiologyInfant NewbornCytochrome P450Hep G2 CellsMiddle Agedmedicine.diseasePhenotypeHigh-Throughput Screening AssaysIsoenzymesOxidative StressPhenotype030104 developmental biologyGene Expression RegulationLiver030220 oncology & carcinogenesisHepatocytesbiology.proteinHepatic stellate cellCancer researchChemical and Drug Induced Liver InjurySteatosisTranscriptomeToxicological Sciences
researchProduct

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control

2018

Objective. In acromegaly, both lipotoxicity secondary to GH excess and insulin resistance have a significant impact on the liver. Ultrasonography has shown poor sensitivity in detecting hepatic steatosis and noninvasive methods have been proposed. We evaluated the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, and we correlated it with disease activity and insulin resistance. Design. Thirty-one patients with newly diagnosed acromegaly were studied at diagnosis and after 12 months of treatment with somatostatin receptor ligands. Methods. Glucose and insulin levels, surrogate estimates of insulin sensitivity, and hepatic steatosis through ultrasonography and …

0301 basic medicinemedicine.medical_specialtyArticle SubjectEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiaCorrelation03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicineAcromegalymedicinelcsh:RC648-665Endocrine and Autonomic SystemsSomatostatin receptorbusiness.industryhepatic steatosisInsulinmedicine.diseaseDisease control030104 developmental biologyLipotoxicitySteatosisbusinessResearch ArticleInternational Journal of Endocrinology
researchProduct